Clinical trials: Bladder Tumors
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors
The purpose of this randomized clinical trial is to learn if 'complex' cancer patients who receive care guided by a health system intervention, Primary Care Connect (PC2) have their risks of cardiovascular disease (CVD) managed…
- Conditions
- Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma)
- Trial name
- ACCESS-PC (NCT06834204)
- Testing
- PC2: Primary Care Connect
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Rutgers, The State University of New Jersey
Bladder Cancer
Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker
Bladder cancer is generally susceptible to immunotherapeutic measures. The investigators will characterize 40 patients with muscle-invasive bladder cancer regarding the existence and frequency of tumorspecific T-cells and…
- Trial name
- NCT01198808
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich
Bladder Cancer, Radical Cystectomy
Comprehensive Optimization At-time of Radical Cystectomy Intervention
The proposed study is aimed at a comprehensive optimization at-time of radical cystectomy (COARC) intervention that focuses on patient optimization throughout the perioperative continuum, from the pre-operative setting to the…
- Trial name
- COARC (NCT05714826)
- Testing
- Preop Intervention and Monitored Recovery, Usual Care
- Sponsor
- University of Texas Southwestern Medical Center
NMIBC, MIBC
A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)
This was a multicenter, prospective, non-interventional, observational cohort study, and the enrolled patients were divided into four cohorts: cohort I was patients with high-risk upper tract urothelial carcinoma (UTUC) (pT3-4 or…
- Conditions
- NMIBC, MIBC, UTUC
- Trial name
- NCT06991868
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University First Hospital
Urinary Bladder Neoplasms
GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile Cystoscopy Unit
The goal of this observational study is to evaluate whether a urinary biomarker (Xpert® Bladder Cancer Detection Test) can be used as a selection tool to decide which patients that should undergo cystoscopy in haematuria work-up…
- Trial name
- NCT06281691
- Testing
- Xpert® Bladder Cancer Detection Test
- Where
- 2 sites in Denmark, Greenland
- Volunteers
- 127 people
- Sponsor
- Jørgen Bjerggaard Jensen
Bladder Cancer
The Application Value of Artificial Intelligence in MRI Precision Diagnosis and Treatment of Bladder Cancer
This study was a prospective, multicenter observational clinical study, A total of 150 patients with bladder malignant tumor who was admitted to the urology department of each center for treatment and underwent electric resection…
- Trial name
- NCT05096533
- Where
- China
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Lung Cancer, Head and Neck Cancer
First-in-human Study of S-588210 (S-488210+S-488211)
The primary objective is to evaluate the safety and tolerability of S-588210 (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.
- Conditions
- Lung Cancer, Head and Neck Cancer, Bladder Cancer, Esophageal Cancer
- Trial name
- NCT04316689
- Testing
- S-488210, S-488211
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Shionogi
Bladder Cancer
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
This is a Phase II/III, open-label, single-arm, multicenter study of intravesical BCG plus N-803 or N-803 only in patients with BCG unresponsive high grade non-muscle invasive bladder cancer (NMIBC).
- Trial name
- NCT03022825
- Testing
- N-803 and BCG, N-803
- Where
- 28 sites in United States
- Volunteers
- 190 people
- Sponsor
- ImmunityBio, Inc.
Bladder Cancer
Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB
The study is intended to investigate whether the improved initial detection and resection of bladder cancer lesions in patients with non-muscle invasive bladder cancer with Hexvix (Cysview) fluorescence cystoscopy/TURB will lead…
- Trial name
- NCT01166230
- Where
- 24 sites in United States, Austria and 3 more
- Volunteers
- 551 people
- Sponsor
- Photocure
Bladder Cancer
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)
This Phase II, single-arm study is designed to evaluate the effect of atezolizumab treatment in participants with locally advanced or metastatic urothelial bladder cancer. Participants will be enrolled into 1 of 2 cohorts.
- Trial name
- NCT02951767
- Testing
- Atezolizumab
- Where
- 77 sites in United States, Canada and 6 more
- Volunteers
- 119 people
- Sponsor
- Hoffmann-La Roche
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003342
- Testing
- filgrastim, carboplatin, doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colon Cancer, Gastric Cancer
Integrated Care Pathway in Oncology (PASSION)
A centralized unit for integrated management of care pathway in Oncology has been created. This unit settles the patients' appointments (biopsy, intravenous device, chemotherapy, imaging, oncologist...).
- Conditions
- Colon Cancer, Gastric Cancer, Pancreatic Cancer, Thoracic Neoplasms
- Trial name
- PASSION (NCT04235556)
- Testing
- Care pathway unit
- Where
- France
- Volunteers
- 1,800 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Urothelial Carcinoma, Head and Neck Cancer
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
This Phase 1 study is designed as a cell dose escalation trial in HLA-A*02:01 and HLA-A*02:06 subjects with MAGE-A10 positive urothelial, melanoma or head and neck tumors.
- Conditions
- Urothelial Carcinoma, Head and Neck Cancer, Melanoma, Bladder Urothelial Carcinoma
- Trial name
- NCT02989064
- Testing
- Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 10 people
- Sponsor
- Adaptimmune
Bladder Cancer, Bladder Disease
The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation
We try to assess the potential role of telomerase reverse transcriptase and MicroRNA (miR-155) in diagnosis of non-muscle-invasive bladder cancer and their correlation with stage and grade of the tumor.
- Conditions
- Bladder Cancer, Bladder Disease, Bladder Neoplasm, Micro-RNA
- Trial name
- NCT03591367
- Testing
- MicroRNAs-155, Human telomerase reverse transcriptase
- Where
- Egypt
- Volunteers
- 115 people
- Sponsor
- Mansoura University
Bladder Neoplasms
Instillation of Gemcitabine in Patients With Superficial Bladder Cancer
A randomized, double-blind, placebo-controlled Phase 3 multicenter study to assess the efficacy and safety of intravesical instillation of gemcitabine versus placebo immediately after transurethral resection of the bladder tumor.
- Trial name
- NCT00191477
- Testing
- Gemcitabine
- Where
- Germany
- Volunteers
- 355 people
- Sponsor
- Eli Lilly and Company
Bladder Cancer
Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as carbogen and niacinamide may make tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00033436
- Testing
- niacinamide, carbogen, radiation therapy
- Where
- 14 sites in United Kingdom
- Volunteers
- 330 people
- Sponsor
- Mount Vernon Cancer Centre at Mount Vernon Hospital
Advanced Cancer, Advanced Malignancies
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
- Trial name
- ARC-25 (NCT05891171)
- Testing
- AB598, Zimberelimab, Fluorouracil
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Arcus Biosciences, Inc.
Non-Muscle-Invasive Bladder Cancer (NMIBC)
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC
This is an open-label, multicenter phase 1 study to evaluate the safety, efficacy, and pharmacokinetics (PK) characteristics of SIM0237 alone or in combination with bacillus Calmette-Guerin (BCG) in participants with…
- Trial name
- NCT06186414
- Testing
- SIM0237, SIM0237 and BCG
- Where
- 14 sites in China
- Volunteers
- 152 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Bladder Cancer
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
The purpose of this study is to determine whether Patients with Locally Advanced or Metastatic Bladder Cancer who receive Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus…
- Trial name
- NCT01126749
- Testing
- Gemcitabine, E7389, Cisplatin
- Where
- 42 sites in United States, Germany and 4 more
- Volunteers
- 92 people
- Sponsor
- Eisai Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.